Ultra-long-acting insulin degludec, an investigational insulin being developed by Novo Nordisk, significantly reduced the rate of hypoglycaemia at night in...
Objective: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents.
Areas covered: The current data available on the use of lixisenatide added to basal insulin for the management of T2DM is reviewed.
The FDA has approved Ryzodeg 70/30 (insulin degludec/insulin aspart injection) from Novo Nordisk, to improve blood sugar (glucose) control in...
The FDA approved the new drug application for Tresiba (insulin degludec injection), from Novo Nordisk, indicated for use alone, or...
Vascular dysfunction has been described in women with a history of gestational diabetes mellitus. Furthermore, previous gestational diabetes mellitus increases...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and...